WALTHAM, Mass. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena ® , the only FDA-approved treatment, More >

The product remains on the market AMAG has 15 days to respond to the FDA AMAG continues to expect its   recently announced tender offer and merger to close in November 2020 WALTHAM, Mass. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received More >

Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses Covis will commence a tender offer to acquire all the outstanding shares of AMAG for a purchase price of $13.75 per share in More >

WALTHAM, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals , Inc. (NASDAQ: AMAG) today announced that Scott Myers , Chief Executive Officer, and Brian Piekos , Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright 22 nd Annual Global Investment Conference More >

Financial guidance reissued to include EBITDA-positive projection for second-half 2020 Strategic shift and momentum build through recent business development activities Brian Piekos promoted to Chief Financial Officer Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass. , Aug. More >

WALTHAM, Mass. , July 28, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 More >

Vyleesi® returned to Palatin Technologies Company focuses on optimizing marketed assets and development of its innovative pipeline WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) --   AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced AMAG and Palatin Technologies, Inc. More >

Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties   Collaboration further advances the development of ciraparantag WALTHAM, Mass. More >

Data from two Phase 2 randomized, placebo-controlled, dose-ranging studies using ciraparantag demonstrate efficacy and safety in the reversal of apixaban and rivaroxaban WALTHAM, Mass. , July 12, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the poster More >

Company initiates CFO & COO succession plan; appoints internal seasoned finance leader as interim CFO Anthony Casciano assumes expanded role as AMAG’s COO WALTHAM, Mass. , June 11, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Edward (Ted) Myles , Chief More >